leisure time -WSS

leisure time

author：focus 2025-08-30 08:11:13 - browse：432

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

knowledge

focus

WSS

Ending health disparities requires full federal government, panel says

Trump allegedly attempted to have surveillance video deleted: Special Counsel

The mammogram wars are not over

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

As the dark side of IVF slowly comes into focus, even more transparency is needed

Marc Tessier

knowledge

leisure time

hotspot

How to save PrEP access — and even expand it

Brain technologies pose threats that are all too real, experts warn

The high cost of giving birth even with insurance

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Apple is now the first public company to be valued at $3 trillion

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

Medical leaders decry Supreme Court decision on affirmative action

Deliver public health messages at the right time

Walensky prepares to leave CDC — and Congress — behind

AltruBio raises $225 million to develop ulcerative colitis drug

knowledge

Class action alleges UnitedHealth concealed DOJ probe

Public health communication lessons from Covid

Brain technologies pose threats that are all too real, experts warn

Is it ever OK for doctors to lie to their patients?

Timeline: Special counsel's probe into Trump's handling of classified documents

Behind warning on Apellis’s eye drug lies a conflict of interest

hotspot

knowledge

focus

focus